In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Immunotherapeutics firm Neovacs SA grosses €10mm in IPO

Executive Summary

Neovacs SA (active immunotherapies inhibiting cytokines) raised €10mm ($13.6mm) in its IPO on NYSE Euronext's Alternext exchange. The company had originally planned to sell up to 3.8mm shares for €5.20-6.00, but then lowered both the number of shares and price range to 2.3mm shares between €4.80-5.60. It ended up offering 2.1mm shares--most of which were bought by institutional investors, and the rest by individuals--at €4.80.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies